- More Info
-
smdi.lsssdc.in
LinkedIn
- Organization
- Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India (Department of Pharmaceuticals)
- Fund type
- Subsidy | Reimbursement
- Source
- Government
- Status
- Active
- Focus area
- Biotech, Medtech, Health & rehabilitation
- Target
- Private Limited Company | Limited Liability Partnership | Government organizations
- Fund range
- Rs. 25 lakhs- Rs. 50 lakhs | Rs. 50 lakhs- Rs. 2cr | Rs. 2 cr- Rs. 10 cr
- Fund stages
- D. Technology Scale-up/ Validation / De-risking | E. Market Entry | F. Expansion
The scheme aims to promote domestic manufacturing of key components, raw materials, and accessories for medical devices (including IVDs), thereby reducing India’s dependence on imports and strengthening domestic value chains.
The Marginal Investment Scheme for Reducing Import Dependence will be implemented over
a three-year period from FY 2024 to FY 2027, with a total budgetary allocation of ₹180 crore
to support eligible manufacturing projects across the medical device sector.
Projects approved under the Scheme shall be completed within two (2) years from the date of
final approval by the Scheme Steering Committee, with the final permissible completion date
being 31.3.2027.
Funds are released only after completion & commissioning of project and completion of other requirements. Funding is equivalent to 10–20% of project cost or max ₹10 Cr on reimbursement basis, post-completion.